Company intelligence / Profile preview

Cellect Biotherapeutics

Kfar Saba, Central District, Israel

Ownership: Private
Employees: ~27
Development stage: Other

Overview

Cellect Biotechnology developed ApoGraft, a technology platform for functionally selecting stem cells to improve safety in regenerative and stem cell therapy; it had a clinical program in bone marrow transplantation for cancer and preliminary collaborations for broader regenerative medicine applications.

Therapeutic areas: HematologyOncology
Modalities: Stem cell therapyBiologic
Industry: Biotech

Partnerships

denovoMATRIX (Technische Universität Dresden)Cell2in Inc.Washington University School of Medicine

Beyond the preview

Go deeper on Cellect Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellect Biotherapeutics.

Explore the full profile